Salarius Pharmaceuticals, Inc. announced that Aundrietta Duncan, Ph.D., director of non-clinical development, will present SP-3164 preclinical data and discuss program progress at the inaugural Molecular Glue Drug Development Summit being held on January 24-26, 2023 in Boston. Dr. Duncan will present in vivo data demonstrating the activity of SP-3164 therapeutic activity in cancer models and in vitro data demonstrating SP-3164's mechanism of action. She also will discuss the overall progress of SP-3164 development.

SP-3164 is an oral, next-generation molecular glue that uses Salarius' deuterium-enabled chiral switching platform to stabilize the preferred (S)-enantiomer of avadomide, an extensively studied clinical compound that has demonstrated encouraging single-agent and combination-therapy clinical efficacy in non-Hodgkin's lymphomas (NHL) and other hematologic malignancies. Addition of deuterium at the chiral center of the molecule prevents conversion to the unwanted (R)-enantiomer allowing for isolation and development of the preferred (S)-enantiomer into a potential new cancer treatment. As such, SP-3164 is a new chemical entity and has been issued a composition of matter patent.

Data presented in December 2022 at the American Society for Hematology Annual Meeting showed compelling SP-3164 activity in lymphoma models and supports SP-3164's potential in NHL for the clinical trial planned to initiate in 2023.